Stevo Jovandic
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stevo Jovandic has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Katarina Zeljic
Faculty of Biology University of Belgrade Belgrade Serbia
2 shared publications - Zvonko Magic
University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade + Military Medical Academy, Institute for Medical Research, Belgrade
2 shared publications Aleksandar Jevtic
Clinic for Orthopedics and Traumatology, Belgrade, Serbia
1 shared publicationBranislav Antic
Military Medical Academy, Clinic for Neurosurgery, Belgrade + University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade
1 shared publication- Dragana Rakasevic
School of Dental Medicine, University of Belgrade, Rankeova , Belgrade, Serbia
1 shared publication Gordana Supic
Institute of Medical Research, Belgrade, Serbia + University of Defence, Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by National Library of Serbia in Archives of Biological Sciences
- Vol. 77 (1) , 71-82
A pilot case-control study of the association of vitamin D-related gene variants with peri-implantitis
This pilot case-control study investigated whether variants in vitamin D-related genes can be used to predict the occurrence of peri-implantitis. Eighty-two patients with at least one dental implant were enrolled. Thirty patients (36.6%) were diagnosed with peri-implantitis, whereas 52 (63.4%) had healthy peri-implant tissues. Clinical parameters, risk factors (history of periodontitis, smoking), and genetic factors were assessed. A buccal mucosa swab was taken for DNA analysis. Four variants in three vitamin D-related genes, VDR (rs2228570), retinoid X receptor alpha (RXRA) (rs3118523, rs7864987), and cytochrome P450 family 27 subfamily B member 1 (CYP27B1) (rs4646536) were genotyped by real-time PCR. There was no difference in the genotype distribution of the variants VDR rs2228570 (P=0.410), RXRA rs3118523, rs7864987 (P=0.789 and P=0.144, respectively), and CYP27B1 rs4646536 (P=0.562) between patients with healthy peri-implant tissues and those affected by peri-implantitis. History of periodontitis, a modified plaque index (mPI), modified bleeding index (mBI), peri-implant pocket depth, and implant location were associated with peri-implantitis incidence. In patients with peri-implantitis, CYP27B1 rs4646536 was associated with mBI (P=0.040), and RXRA rs7864987 was associated with implant position (P=0.009). We conclude that the variants of vitamin D-related genes, VDR, RXRA, and CYP27B1, cannot be used as molecular markers for peri-implantitis.
- 1 January 2025
- Published by National Library of Serbia in Archives of Biological Sciences
- Vol. 77 (1) , 71-82
Open AccessA pilot case-control study of the association of vitamin D-related gene variants with peri-implantitis
This pilot case-control study investigated whether variants in vitamin D-related genes can be used to predict the occurrence of peri-implantitis. Eighty-two patients with at least one dental implant were enrolled. Thirty patients (36.6%) were diagnosed with peri-implantitis, whereas 52 (63.4%) had healthy peri-implant tissues. Clinical parameters, risk factors (history of periodontitis, smoking), and genetic factors were assessed. A buccal mucosa swab was taken for DNA analysis. Four variants in three vitamin D-related genes, VDR (rs2228570), retinoid X receptor alpha (RXRA) (rs3118523, rs7864987), and cytochrome P450 family 27 subfamily B member 1 (CYP27B1) (rs4646536) were genotyped by real-time PCR. There was no difference in the genotype distribution of the variants VDR rs2228570 (P=0.410), RXRA rs3118523, rs7864987 (P=0.789 and P=0.144, respectively), and CYP27B1 rs4646536 (P=0.562) between patients with healthy peri-implant tissues and those affected by peri-implantitis. History of periodontitis, a modified plaque index (mPI), modified bleeding index (mBI), peri-implant pocket depth, and implant location were associated with peri-implantitis incidence. In patients with peri-implantitis, CYP27B1 rs4646536 was associated with mBI (P=0.040), and RXRA rs7864987 was associated with implant position (P=0.009). We conclude that the variants of vitamin D-related genes, VDR, RXRA, and CYP27B1, cannot be used as molecular markers for peri-implantitis.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (11) , 1063-1072
Pathogenic TP53 mutations influence chemotherapy response and survival rate of HPV-negative oral carcinomas
Background/Aim. Oral squamous cell carcinoma (OSCC) is the most common tumor type of head and neck carcinomas, characterized by a high recurrence rate and patients? poor survival. Further elucidation of the function and regulation of the TP53, a pivotal tumor suppressor gene, would provide advances in predicting the clinical behavior, prognosis, and chemotherapy response of OSCC patients. Thus, we investigated the association of TP53 gene mutations with survival and response to cisplatin chemotherapy in human papilloma virus (HPV)-negative OSCC patients. Methods. The potential clinical relevance of TP53 mutations was analyzed in 82 patients with HPV-negative OSCC. All patients underwent radiotherapy, and 25 patients received cisplatin chemotherapy. A negative HPV status was deter-mined by type-specific polymerase chain reaction (PCR) for high-risk HPV 16, 18, 31, and 33. Targeted sequencing of TP53 exons 4?8 was assessed by Sanger sequencing. Results. Of 82 HPV-negative OSCC patients, 49 (59.79%) had TP53 mutations, and 26 patients (31.7%) carried pathogenic TP53 mutations. Patients with pathogenic TP53 mutations had significantly reduced overall survival (p = 0.009). Recurrence status, but not TP53 mutations, was an independent marker of poor survival in our cohort [hazard ratio (HR) = 4.733, 95% confidence interval (95% CI): 2.027?11.053, p = 0.0001]. In the sub-cohort of patients who underwent cisplatin-based chemotherapy, pathogenic TP53 mutations were predictors of poor response to chemotherapy (p = 0.026). Conclusion. Our findings indicate that pathogenic TP53 mutations in HPV-negative OSCC tumors could be a prognostic marker of patients? reduced overall survival. In addition, pathogenic TP53 mutations in HPV-negative OSCC could be a marker of poor chemotherapy response of OSCC patients.
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (11) , 1063-1072
Open AccessPathogenic TP53 mutations influence chemotherapy response and survival rate of HPV-negative oral carcinomas
Background/Aim. Oral squamous cell carcinoma (OSCC) is the most common tumor type of head and neck carcinomas, characterized by a high recurrence rate and patients? poor survival. Further elucidation of the function and regulation of the TP53, a pivotal tumor suppressor gene, would provide advances in predicting the clinical behavior, prognosis, and chemotherapy response of OSCC patients. Thus, we investigated the association of TP53 gene mutations with survival and response to cisplatin chemotherapy in human papilloma virus (HPV)-negative OSCC patients. Methods. The potential clinical relevance of TP53 mutations was analyzed in 82 patients with HPV-negative OSCC. All patients underwent radiotherapy, and 25 patients received cisplatin chemotherapy. A negative HPV status was deter-mined by type-specific polymerase chain reaction (PCR) for high-risk HPV 16, 18, 31, and 33. Targeted sequencing of TP53 exons 4?8 was assessed by Sanger sequencing. Results. Of 82 HPV-negative OSCC patients, 49 (59.79%) had TP53 mutations, and 26 patients (31.7%) carried pathogenic TP53 mutations. Patients with pathogenic TP53 mutations had significantly reduced overall survival (p = 0.009). Recurrence status, but not TP53 mutations, was an independent marker of poor survival in our cohort [hazard ratio (HR) = 4.733, 95% confidence interval (95% CI): 2.027?11.053, p = 0.0001]. In the sub-cohort of patients who underwent cisplatin-based chemotherapy, pathogenic TP53 mutations were predictors of poor response to chemotherapy (p = 0.026). Conclusion. Our findings indicate that pathogenic TP53 mutations in HPV-negative OSCC tumors could be a prognostic marker of patients? reduced overall survival. In addition, pathogenic TP53 mutations in HPV-negative OSCC could be a marker of poor chemotherapy response of OSCC patients.
- Open Access
- 1 January 2020
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 77 (6) , 631-636
Association of PAX3 and TMTC2 gene polymorphism with the face morphology change after excision of skin tumors
Background/Aim. The group of genes, known as PAX (Paired box), has a great role in organogenesis, as well as in maintaining the normal function of certain cells after the birth. In addition to these genes, the impact on the organogenesis, at the cellular level, has a transmembrane tetratricopeptid group of genes (TMTC). The term polymorphism in the human genome implies variations in the hereditary basis that occur in human populations, the presence of two or more different alleles of one genome in the population. The aim of the work is to determine whether there is an association of PAX3 and TMTC2 genes polymorphism with changes of face morphology after the skin tumor excision and direct suture closure. Methods. The study included 130 patients of both sexes, older than 50 years, with the medical indication for the elliptical surgical excision of skin tumor. DNA was isolated from 5ml of peripheral blood. Gene polymorphisms were analyzed with pre-designed SNP assays, by allelic discrimination method on REAL-TIME apparatus. The patients had a laser scanning preoperatively, 7 days and 90 days postoperatively, giving x, y and z coordinates of 5 cephalometric points on the face, for every patient, which determined the shape of the medial cheek region. The shape of the medial cheek region, as well as the coordinates of 5 cepahlometric points, among genotypes was compared, preoperatively, 7 days and 90 days postoperatively, in both genes. Results. A statistically significant difference in the shape of the medial cheek region between wild-type and mutant of PAX3 gene was found preoperatively, while the statistically significant difference in the shape of the medial cheek region was not found between wild-type and heterozygote, nor between wild-type vs. heterozygote and mutant of PAX3 gene, nor among genotypes of TMTC2 gene. Post-operatively, 7 days and 90 days, there was no statistically significant difference in the shape of the examined region among genotypes in both genes. Conclusion. Polymorphisms of PAX3 and TMTC2 genes are not associated with the change in the morphology of the face after the skin tumor excision and direct suture closure of the defect.
- 1 January 2020
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 77 (6) , 631-636
Open AccessAssociation of PAX3 and TMTC2 gene polymorphism with the face morphology change after excision of skin tumors
Background/Aim. The group of genes, known as PAX (Paired box), has a great role in organogenesis, as well as in maintaining the normal function of certain cells after the birth. In addition to these genes, the impact on the organogenesis, at the cellular level, has a transmembrane tetratricopeptid group of genes (TMTC). The term polymorphism in the human genome implies variations in the hereditary basis that occur in human populations, the presence of two or more different alleles of one genome in the population. The aim of the work is to determine whether there is an association of PAX3 and TMTC2 genes polymorphism with changes of face morphology after the skin tumor excision and direct suture closure. Methods. The study included 130 patients of both sexes, older than 50 years, with the medical indication for the elliptical surgical excision of skin tumor. DNA was isolated from 5ml of peripheral blood. Gene polymorphisms were analyzed with pre-designed SNP assays, by allelic discrimination method on REAL-TIME apparatus. The patients had a laser scanning preoperatively, 7 days and 90 days postoperatively, giving x, y and z coordinates of 5 cephalometric points on the face, for every patient, which determined the shape of the medial cheek region. The shape of the medial cheek region, as well as the coordinates of 5 cepahlometric points, among genotypes was compared, preoperatively, 7 days and 90 days postoperatively, in both genes. Results. A statistically significant difference in the shape of the medial cheek region between wild-type and mutant of PAX3 gene was found preoperatively, while the statistically significant difference in the shape of the medial cheek region was not found between wild-type and heterozygote, nor between wild-type vs. heterozygote and mutant of PAX3 gene, nor among genotypes of TMTC2 gene. Post-operatively, 7 days and 90 days, there was no statistically significant difference in the shape of the examined region among genotypes in both genes. Conclusion. Polymorphisms of PAX3 and TMTC2 genes are not associated with the change in the morphology of the face after the skin tumor excision and direct suture closure of the defect.
- Open Access
- 1 January 2016
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 73 (1) , 83-87
Successful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of langerhans cell histiocytosis
Introduction. Erdheim-Chester disease (ECD) is a rare, systemic form of non-Langerhans cell histiocytosis of the juvenile xantho-granuloma family with characteristic bilateral symmetrical long bone osteosclerosis, associated with xanthogranulomatous extras-keletal organ involvement. In ECD, central nervous system (CNS) and orbital lesions are frequent, and more than half of ECD patients carry the V600E mutation of the proto-oncogene BRAF. The synchronous or metachronous development of ECD and Langerhans cell histiocytosis (LCH) in the same patients is rare, and the possible connection between them is still obscure. Cladribine is a purine substrate analogue that is toxic to lymphocytes and monocytes with good hematoencephalic penetration. Case report. We presented a 23-year-old man successfully treated with cladribine due to BRAF V600E-mutation-negative ECD with bilateral orbital and CNS involvement. ECD developed metachronously, 6 years after chemotherapy for multisystem LCH with complete disease remission and remaining central diabetes insipidus. During ECD treatment, the patient received 5 single-agent chemotherapy courses of cladribine (5 mg/m2 for 5 consecutive days every 4 weeks), with a reduction in dose to 4 mg/m2 in a fifth course, delayed due to severe neutropenia and thoracic dermatomal herpes zoster infection following the fourth course. Radiologic signs of systemic and CNS disease started to resolve 3 months after the end of chemotherapy, and CNS lesions completely resolved within 2 years after the treatment. After 12-year follow-up, there was no recurrence or appearance of new systemic or CNS xanthogranu-lomatous lesions or second malignancies. Conclusion. In accordance with our findings and recommendations provided by other authors, cladribine can be considered an effective alternative treatment for ECD, especially with CNS involvement and BRAF V600E-mutation-negative status, when interferon-? as the first-line therapy fails.
- 1 January 2016
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 73 (1) , 83-87
Open AccessSuccessful treatment with cladribine of Erdheim-Chester disease with orbital and central nervous system involvement developing after treatment of langerhans cell histiocytosis
Introduction. Erdheim-Chester disease (ECD) is a rare, systemic form of non-Langerhans cell histiocytosis of the juvenile xantho-granuloma family with characteristic bilateral symmetrical long bone osteosclerosis, associated with xanthogranulomatous extras-keletal organ involvement. In ECD, central nervous system (CNS) and orbital lesions are frequent, and more than half of ECD patients carry the V600E mutation of the proto-oncogene BRAF. The synchronous or metachronous development of ECD and Langerhans cell histiocytosis (LCH) in the same patients is rare, and the possible connection between them is still obscure. Cladribine is a purine substrate analogue that is toxic to lymphocytes and monocytes with good hematoencephalic penetration. Case report. We presented a 23-year-old man successfully treated with cladribine due to BRAF V600E-mutation-negative ECD with bilateral orbital and CNS involvement. ECD developed metachronously, 6 years after chemotherapy for multisystem LCH with complete disease remission and remaining central diabetes insipidus. During ECD treatment, the patient received 5 single-agent chemotherapy courses of cladribine (5 mg/m2 for 5 consecutive days every 4 weeks), with a reduction in dose to 4 mg/m2 in a fifth course, delayed due to severe neutropenia and thoracic dermatomal herpes zoster infection following the fourth course. Radiologic signs of systemic and CNS disease started to resolve 3 months after the end of chemotherapy, and CNS lesions completely resolved within 2 years after the treatment. After 12-year follow-up, there was no recurrence or appearance of new systemic or CNS xanthogranu-lomatous lesions or second malignancies. Conclusion. In accordance with our findings and recommendations provided by other authors, cladribine can be considered an effective alternative treatment for ECD, especially with CNS involvement and BRAF V600E-mutation-negative status, when interferon-? as the first-line therapy fails.